Allergy Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Allergy Therapeutics generated cash of -$32,137,999, which is less than the previous year. Cash used in financing activities reached the amount of $31,431,000 last year. Net change in cash is therefore -$1,930,000.
Cash Flow
| 2010 | 1.70M | -2.00M | 4.89M |
|---|---|---|---|
| 2011 | -2.02M | -2.28M | 764K |
| 2012 | 2.88M | -1.56M | -2.73M |
| 2016 | -11.83M | -1.49M | 12.53M |
| 2018 | -3.80M | -2.50M | -294K |
| 2020 | 12.27M | -2.77M | -110K |
| 2021 | 8.51M | -2.75M | -2.03M |
| 2023 | -30.91M | -4.66M | 29.91M |
| 2024 | -32.13M | -1.19M | 31.43M |
AGY.L Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.84M | 20.51M | 36.96M | 27.44M | 22.12M | 21.19M | 1.04M | 4.52M | -26K |
Operating activities | |||||||||
Net income | -40.21M | -43.07M | 2.88M | 7.05M | -7.53M | -13.07M | 823K | -2.66M | 586K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 4.31M | 4.22M | 4.13M | 3.91M | 1.76M | 1.56M | 1.89M | 1.69M | 1.42M |
Stock-based compensation expense | 0 | 114K | 635K | 794K | 985K | 327K | 131K | 147K | 193K |
| Deferred income tax benefit | 0 | 114K | 635K | 794K | 985K | 327K | 131K | 147K | 193K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 144K | 3.38M | 2.14M | 3.69M | 3.30M | -368K | 0 | 0 | 0 |
Inventories | -1.23M | -183K | -1.11M | -706K | -1.33M | -585K | 272K | 73K | -911K |
Accounts payable | 788K | 4.81M | 548K | -2.39M | -1.76M | -497K | 0 | 0 | 0 |
Cash generated by operating activities | -32.13M | -30.91M | 8.51M | 12.27M | -3.80M | -11.83M | 2.88M | -2.02M | 1.70M |
Investing activities | |||||||||
Purchases Of Investments | 0 | -159K | -194K | -228K | -367K | -260K | -311K | -313K | -319K |
Investments In Property Plant And Equipment | -3.40M | -4.66M | -2.56M | -2.54M | -2.00M | -1.23M | -1.26M | -1.23M | -1.69M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -740K | 0 |
Cash generated by investing activities | -1.19M | -4.66M | -2.75M | -2.77M | -2.50M | -1.49M | -1.56M | -2.28M | -2.00M |
Financing activities | |||||||||
Common Stock Issued | 2.41M | 6.48M | 4K | 1K | 2K | 10.97M | 12.61M | 1K | 25.74M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 32.57M | 25.03M | -132K | -111K | -296K | 1.56M | -23.02M | -8.26M | -43.28M |
Cash used in financing activities | 31.43M | 29.91M | -2.03M | -110K | -294K | 12.53M | -2.73M | 764K | 4.89M |
Net Change In Cash | -1.93M | -5.67M | 3.31M | 9.52M | -6.58M | 2.20M | -1.45M | -3.47M | 4.54M |
Cash at end of period | 12.91M | 14.84M | 40.27M | 36.96M | 15.53M | 23.40M | -409K | 1.04M | 4.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |